Recap: Fulgent Genetics Q4 Earnings

Shares of Fulgent Genetics FLGT moved higher by 24.0% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 15400.00% year over year to $6.20, which beat the estimate of $4.05.

Revenue of $294,978,000 rose by 3417.09% year over year, which beat the estimate of $199,440,000.

Guidance

Fulgent Genetics Sees FY21 EPS ~$12.50 Vs. $11.55 Est., Sales ~$800M Vs. $600.24M Est.

Details Of The Call

Date: Mar 04, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/jf6vsajc

Technicals

52-week high: $189.89

52-week low: $6.70

Price action over last quarter: Up 246.36%

Company Profile

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to a disease and enhanced disease treatment and prognosis.

FLGT Logo
FLGTFulgent Genetics Inc
$21.00-3.31%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
70.46
Growth
15.17
Quality
Not Available
Value
74.49
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Comments
Loading...